Trial Profile
Prospective Observation of Cardiac Safety With Proteasome Inhibition
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 May 2023
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Carfilzomib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms PROTECT
- 24 Mar 2023 Results assessing proteomics analysis of Carfilzomib (Cfz) related heart failure in multiple myeloma patients from prospective study of cardiac events during proteasome inhibitor therapy, presented at the 124th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 18 Mar 2022 Results (n=57)performing untargeted metabolomics on the baseline plasma samples in MM patients receiving CFZ to build a predictive model for CFZ-CVAE based on metabolomic signals, presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 10 Sep 2020 Status changed from active, no longer recruiting to completed.